It's always good to be reminded of analysts reports from time to time but imo it's also worth conducting research on the analysts themselves:
From my experience you might find that National Securities, Jason Kolbert couldn't call a chook raffle if he tried whilst Southern Cross's Stuart Roberts I'd consider one of the best in the field of the listed bio spec market.
For The Trader Central to suggest that they both have similar targets is also right off the mark.
Sth Cross analyst, Stuart Roberts set a 12 month target of 60c for PRR in May 2010 when the sp was only 14c - If the Nasdaq listing is announced this month I believe this target is still not out of reach.
National Securities, Jason Kolbert on the other hand set a 5 year target of 62c for PRR in February 2011 when the sp was 23c. 62c by 2016?
If any analyst believes that PRR's CVac (which Jason calls CVAX in his report) once listed on the Nasdaq and approved by FDA to become a new blockbuster drug, will only see the sp appreciate 39c by 2016, imho, he's in the wrong job.
National Securities should've shot him for exposing himself and them as a circus of clowns.
PRR Price at posting:
27.1¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)